Donald Trump, the president-elect, will take his place in the Oval Office in January 2017, voted there by the American public.
With the focus – up to now – appearing to be on finance and the overhaul of reforms put in place by Dodd-Frank, it appears that Trump has another target within his sight – the Food and Drug Agency (FDA) and a list of possible reforms.
Mentioning the FDA on the day after his election success, Trump has indicated that these reforms will take place as part of his policy on healthcare to focus more on patient care and the manufacture of medical products that change lives. Those who try to take advantage of the terminally ill by encouraging patients to use untested drugs have had all legal responsibility taken away from them following the signing of a ‘right-to-try’ law by Mike Pence, vice-president elect.
Protection from the drugs that do not work
It is widely believed that allowing drugs to be marketed without the approval of the FDA, which often involves clinical trial services from companies such as http://www.gandlscientific.com/clinical-trial-services/, means patients who are already incredibly vulnerable could find themselves at risk of taking inappropriate, ineffective or even dangerous drugs. It seems that Trump will be going ahead with the controversial new plan to make current marketing barriers faced by drug companies easier to navigate, if not getting rid of them altogether.
This is expected to have a knock-on effect on the price that American citizens pay for medical health insurance – in that it will rise – for potentially receiving drugs that are completely ineffective. With concerns being raised about how far the standards should drop, there are still some people who believe that taking unregulated drugs is well worth the risk, particularly those with rare diseases and illness for which a cure has not yet been found. Despite this, many of the drugs do work, although it is clear that a lot of research still needs to be done.
There is evidence to suggest that drugs the FDA has gone on to approve, against the advice of world-leading scientists, exist. This sadly points to the fact that FDA staff have found themselves under considerable pressure to push drug regulation through after receiving threats and abuse from members of the American public.